Results 81 to 90 of about 175,639 (315)

Tumor‐Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities

Advanced Science, EarlyView.
ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley   +1 more source

Role of gemcitabine in the treatment of advanced and metastatic breast cancer [PDF]

, 2003
Gemcitabine is an antimetabolite drug with proven antitumor activity and tolerability in metastatic breast cancer. In a total of nine studies, gemcitabine monotherapy has reached response rates of up to 37% in the first-line setting, 26% in the second ...
Heinemann, Volker
core   +1 more source

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa, Itaru Yasufuku, Hironori Ishigami, Masahiro Yura, Takanobu Yamada, Shigeaki Baba, Takeshi Kubota, Erina Nagai, Seito Fujibayashi, Mitsumasa Yoshida, Takahiro Kinoshita, Nobuhisa Matsuhashi, Masanori Terashima   +12 more
wiley   +1 more source

Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. [PDF]

, 2018
Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an
Chishima, Takashi, Eilber, Fritz C, Endo, Itaru, Hiroshima, Yukihiko, Hoffman, Robert M, Igarashi, Kentaro, Kawaguchi, Kei, Kiyuna, Tasuku, Li, Yunfeng, Matsuyama, Ryusei, Miyake, Kentaro, Miyake, Masuyo, Momiyama, Masashi, Murakami, Takashi, Nelson, Scott D, Razmjooei, Sahar, Russell, Tara A, Singh, Arun S, Singh, Shree Ram, Wangsiricharoen, Sintawat, Yoon, Sang Nam, Zhang, Zhiying   +21 more
core   +2 more sources

Preoperative Gemcitabine/Nab‐Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer: A Comparative Analysis With Preoperative Chemoradiation Therapy Using Gemcitabine Alone

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Although NCCN guidelines recommend preoperative therapy for borderline resectable pancreatic cancer (BR‐PC), it is still unclear which regimen is better. The study objective was to elucidate the prognostic significance of neoadjuvant chemoradiotherapy (NACRT) with gemcitabine/nab‐paclitaxel (GnP‐RT) compared to gemcitabine alone ...
Hirofumi Akita, Hidenori Takahashi, Yousuke Mukai, Masahiko Kubo, Shinichiro Hasegawa, Masayoshi Yasui, Takeshi Omori, Hiroshi Miyata, Hiroshi Wada, Kunihito Gotoh   +9 more
wiley   +1 more source

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

High incidence of Angina pectoris in patients treated with 5-fluorouracil - A planned surveillance study with 102 patients [PDF]

, 2003
Objective: Angina pectoris, arrhythmic sudden death and myocardial infarction, all these cardiac events have occasionally been reported during 5-fluorouracil (5-FU) chemotherapy.
Lersch, C., Reindl, L., Scherpinski, U., Seyfarth, M., Wacker, A.   +4 more
core   +1 more source

Relationship Between the Product of Pre‐Treatment Neutrophil and Monocyte Counts and Clinical Outcomes in Rectal Cancer With Suspected Lateral Lymph Node Metastasis

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim A novel systemic inflammatory response marker, the neutrophil × monocyte value (NM value), has been identified as a negative predictive factor for responses to chemoradiotherapy in rectal cancer. However, the clinical implications of the NM value remain unknown.
Takayoshi Sasaki, Shinya Abe, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Yuzo Harada, Soichiro Ishihara   +9 more
wiley   +1 more source

Successful desensitization with 5-fluorouracil in a patient who developed anaphylaxis after 5-fluorouracil infusion

Alergologia Polska
5-Fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of gastrointestinal tract, skin and breast cancers. Hypersensitivity reactions may occur due to the use of chemotherapeutic drugs.
Mehmet Erdem Çakmak, Nida Oztop, Osman Ozan Yeğit   +2 more
doaj   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source